Instruction for Contributors
Template File
Manuscript template Author contribution form Patient consent form Response to reviewer template Endnote styleAll the papers submitted to MedPharmRes journal are peer-reviewed. MedPharmRes applies high standards to the peer- review process to ensure appropriate methodological design and valid results. We emphasize on accuracy of research methodology and high ethical standards.
How MedPharmRes will Handle Your Paper?
Once you submit your paper, the official team will check your paper quickly to assess the following:
1. The human and animal ethics is properly conducted
2. Financial disclosures
3. Any conflict of interest addressed
4. The style and format of the manuscript
5. The plagiarism
6. Copyright (Journal Publishing Agreement)
This step is very crucial before sending the paper to Editors. The official team handle this step quickly and usually will not take more than two working days.
If any additional data needed, we will send the paper back to authors to make sure all the needed data are addressed efficiently.
After the manuscript passes the first check, it will be sent to Editor in Chief
Editorial Process
The Editors will assess the quality of research and evaluate your manuscript, then the editor will assign appropriate reviewers for the manuscript. The duration of this step will be no more than two weeks.
Peer Review Process
MedPharmRes peer-review is double blinded (both the authors and reviewers keep their anonymity). The Editor will invite two or three reviewers to review your manuscript. Once they accept to review the manuscript, the reviewers are given ten days to comment. We will ensure that the process pass smoothly and rapidly. Any delays will be addressed and we will inform the authors with the updates and whether there is further delay or not.
The reviewers will send the comments to the editor who will review them and send the comments of both editors and reviewers to the authors.
How the Authors should Respond?
In accordance with our editorial process, authors are allotted a 90-day window to respond to reviewers' and editors' comments. During this period, authors are expected to address the specific points raised by the reviewers and editors, revising their manuscript as needed. Subsequently, the handling editor will engage in further dialogue with the authors to ensure that their manuscript aligns with the journal's quality standards. Upon completion of this stage, the manuscript will be forwarded to the Editor-in-Chief for the final decision. Notification of the final decision will be communicated via email to the corresponding author.
How to Submit Article:
Please access to http://www.editorialmanager.com/medpharmres to submit your articles.
Author(s) should number words’ lines in their manuscript and carefully check English typos and grammar before submission. Manuscripts with major language issues may be rejected.
Article Types
Original Articles
Original articles are full-length papers describing novel findings across all areas of immunology, including both basic and clinical studies. Recommended limit of the text (excluding references) is 6,000 words.
Review Articles
Review articles are full-length papers aiming to provide new frameworks for recent findings, or balanced views of a field or topic. Recommended limit of the text is 7,500 words. Recommended limit of references is 100.
Case Reports & Brief Communications
Case Reports and Brief communications are short articles reporting findings of immediate impact. Results and Discussion sections may be combined. Recommended limit of the text (excluding references) is 3,000 words.
Correspondences
Correspondences are rapid and concise reports of cutting-edge research. Correspondences also include a reader’s comment on an article published in MedPharmRes and a reply from the authors. Abstract is not required. Maximum word limit is 1,200 words including references, figures and tables. Maximum number of figure or table is 1. Recommended limit of references is 10.
Editorials
Editorials are invited perspectives aiming to provide new insights into active fields of immunological research. Abstract is not required. Maximum word limit is 1,000 words including references, figures and tables. Maximum number of figure or table is 1. Recommended limit of references is 10.
Form of Manuscript
The article should contain an abstract, key words, main text, acknowledgements, references and etc.
Title page
1. The title should be limited to 20 words and there should be no abbreviations.
2. The running title should be limited to 10 words.
3. Full names and institutional addresses of all authors should be provided.
4. The description of the corresponding author should include name, institution, mailing address, telephone, and e-mail address.
Abstract
1. The Abstract should not exceed 250 words.
2. Summarize the aim(s) and findings of the work in regular typeface, consisting of introduction, methods, results, and conclusions.
- Introduction: provide background information and state the aim of the study or the hypothesis that was tested.
- Methods: include the setting for the study, the subjects, sample size and sampling, the diagnosis or intervention, data collection and tools, and statistical analysis.
- Results: present as clearly as possible the outcomes of the study and statistical significance.
- Conclusions: briefly discuss the data and emphasize the significance of the results.
Keywords
Three to five keywords are listed.
It is recommended to use MeSH terms (https://www.ncbi.nlm.nih.gov/mesh) as keywords if possible.
Introduction
The introduction section should explain the rationale for performing the study, background, objectives, and hypothesis.
Materials and Methods
The methods section should:
- Use subheadings to separate different methodologies.
- Describe established methods briefly, and simply cite a reference where readers can find more detail
- State all statistical tests and parameters
Results
This section should include the findings of the study including, if appropriate, results of statistical analysis which must be included either in the text or as tables and figures. The results section may include subheadings.
Discussion
This section should discuss the implications of the findings in context of existing research and highlight limitations of the study. For study protocols and methodology manuscripts this section should include a discussion of any practical or operational issues involved in performing the study and any issues not covered in other sections.
Conclusion
This section should briefly discuss the data and emphasize the significance of the results.
Competing Interests
MedPharmRes requires authors to declare all competing interests including financial or non-financial support related to their work. Where authors have no competing interests, the statement should read “No potential conflict of interest relevant to this article was reported”. The editor may ask for further information relating to competing interests.
Acknowledgments
Please acknowledge anyone who contributed towards the article who does not meet the criteria for authorship including anyone who provided professional writing services or materials. Authors should obtain permission to acknowledge from all those mentioned in the Acknowledgements section.
Author’s Contributions
What authors have done for the study should be described in this section. To qualify for authorship, all contributors must meet at least one of the seven core contributions by CRediT (conceptualization, methodology, software, validation, formal analysis, investigation, data curation), as well as at least one of the writing contributions (original draft preparation, review and editing). Authors may also satisfy the other remaining contributions; however, these alone will not qualify them for authorship.
Contributions will be published with the final article, and they should accurately reflect contributions to the work. The submitting author is responsible for completing this information at submission, and it is expected that all authors will have reviewed, discussed, and agreed to their individual contributions ahead of this time.
Ethics Approval and Consent to Participate
Any investigations involving humans and animals should be approved by the Institutional Review Board (IRB) and the Animal Care and Use Committee, respectively, of the institution where the study took place. MedPharmRes will not consider any studies involving humans or animals without the appropriate approval. Informed consent should be obtained, unless waived by the IRB, from patients who participated in clinical investigations. Human subjects should not be identifiable, such that patients’ names, initials, hospital numbers, dates of birth, or other protected healthcare information should not be disclosed. If experiments involve animals, the research should be based on national or institutional guidelines for animal care and use. Articles that address any investigation involving humans and animals submitted to MedPharmRes should include a description about whether the study was conducted under an approval by the IRB (with or without patient informed consent) and the Animal Care and Use Committee, respectively, of the institution where the study was conducted. MedPharmRes can request the statement of approval by the IRB or the Animal Care and Use Committee for other types of articles when necessary.
References
References should be formatted according to the Vancouver reference (NLM) style.
Example reference style:
1. Journal articles with less than 6 authors
• Jun BC, Song SW, Park CS, Lee DH, Cho KJ, Cho JH. The analysis of maxillary sinus aeration according to aging process: volume assessment by 3-dimensional reconstruction by high-resolutional CT scanning. Otolaryngol Head Neck Surg. 2005;132(3):429-34.
2. Journal articles with more than 6 authors:
• Hallal AH, Amortegui JD, Jeroukhimov IM, Casillas J, Schulman CI, Manning RJ, et al. Magnetic resonance cholangiopancreatography accurately detects common bile duct stones in resolving gallstone pancreatitis. J Am Coll Surg. 2005;200(6):869-75.
3. Standard book with initials for authors:
• Modlin IM, Sachs G. Acid related diseases: biology and treatment. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2004. 522 p.
4. Citing a contributed chapter:
• Rojko JL, Hardy WD Jr. Feline leukemia virus and other retroviruses. In: Sherding RG, editor. The cat: diseases and clinical management. New York, NY: Churchill Livingstone; 1989. p. 229-332.
5. Conference paper
• Kim HW. Challenges and future directions on journal “perspectives in nursing science” in Korea. Poster session presented at: Asia Pacific Association of Medical Journal Editors Convention 2013; 2013 Aug 2-4; Tokyo, Japan.
6. Proceeding paper
• Brody AL. Meat packaging: past, present and future. In: Proceedings of the 55th Reciprocal Meat Conference; 2002; Michigan, MI.
7. Dissertation
• Kim K. Quantum critical phenomena in superfluids and superconductors [Ph.D. dissertation]. Pasadena, CA: California Institute of Technology; 1991.
8. Scientific and technical report
• Kim SN, Park JR, Bae HS, Kown KW, Joo DB, Lim ST, et al. A study on the meta evaluation of Korean university evaluation. Seoul: Korean Educational Development Institute; 2004. Report No.: CR 2004-45.
9. Internet
• Doe J. Title of subordinate document [Internet]. Royal Society of Chemistry. 1999 [cited 2019 Aug 4]. http://www.rsc.org/dose/title of subordinate document
Tables and Figures
Tables must have a descriptive title and if numerical measurements are given, the units should be included in the column heading. All tables must be submitted as a text type.
Figures must be supplied as either TIFF or JPG files with a resolution at least 300 dpi.
The Table and Figure number and title should be typed. They should be numbered sequentially using Arabic numbers (e.g., Table 1, Table 2; Fig. 1, Fig. 2). All figures and tables should be numbered and cited in order of appearance in the text.
Cover letter, Title page, Manuscript, and Tables and Figures should be prepared in separated files.
Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals:
MedPharmres adheres to the ICMJE recommendations (https://www.icmje.org/recommendations/).
Alteration to Authorship or Contributorship:
Any change in authors and/or contributors after initial submission must be approved by all authors. This applies to additions, deletions, changes of order to the authors, or contributions being attributed differently. Any alterations must be explained to the editor. The editor may contact any of the authors and/or contributors to ascertain whether they have agreed to any alteration. The change in authors and/or contributors is not accepted after the manuscript is accepted.
Deadline for Submission:
There is no specific deadline for submission. Submissions are reviewed on a rolling basis as they are received.
Contact:
Website: https://www.medpharmres.com Office address: 217 Hong Bang street, District 5, Ho Chi Minh City, VietnamTel: +84-28-3855-8411
Fax: +84-28-3855-2304
E-mail: medpharmres@ump.edu.vn